Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition.

PubWeight™: 0.87‹?›

🔗 View Article (PMC 4037727)

Published in J Clin Endocrinol Metab on February 11, 2014

Authors

Alex J Polotsky1, Amanda A Allshouse, Sybil L Crawford, Sioban D Harlow, Naila Khalil, Rasa Kazlauskaite, Nanette Santoro, Richard S Legro

Author Affiliations

1: Department of Obstetrics and Gynecology (A.J.P., A.A.A., N.S.), University of Colorado Denver, and Department of Biostatistics and Informatics (A.A.A.), School of Public Health, University of Colorado Denver, Aurora, Colorado 80045; Department of Epidemiology, Preventive, and Behavioral Medicine (S.L.C.), University of Massachusetts Medical School, Worcester, Massachusetts 01655; School of Public Health (S.D.H.), University of Michigan, Ann Arbor, Michigan 48109; Department of Community Health (N.K.), Boonshoft School of Medicine, Wright State University, Dayton, Ohio 45420; Department of Endocrinology and Preventive Cardiology (R.K.), Rush University, Chicago, Illinois 60612; and Department of Obstetrics and Gynecology (R.S.L.), Penn State College of Medicine, Hershey, Pennsylvania 17033.

Articles cited by this

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod (2004) 12.27

Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates. J Am Coll Cardiol (2007) 7.13

Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care (2004) 6.68

Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab (2010) 2.48

Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2005) 2.28

Retracted Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab (2008) 2.21

Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA (2001) 1.90

Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab (2011) 1.81

Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women's Health Across the Nation (SWAN). Arch Gen Psychiatry (2010) 1.73

Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) (2000) 1.66

Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab (2006) 1.59

The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertil Steril (2006) 1.56

Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol (1998) 1.43

Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol (1998) 1.30

Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation. Am J Epidemiol (2009) 1.29

Glucose and insulin components of the metabolic syndrome are associated with hyperandrogenism in postmenopausal women: the atherosclerosis risk in communities study. Am J Epidemiol (2004) 1.25

Sex hormone levels and subclinical atherosclerosis in postmenopausal women: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis (2008) 1.22

Higher serum testosterone concentration in older women is associated with insulin resistance, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab (2009) 1.16

Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril (2000) 1.13

Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod (2000) 1.10

American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. Endocr Pract (2005) 1.00

Testosterone, sex hormone-binding globulin and free androgen index among adult women: chronological and ovarian aging. Hum Reprod (2009) 0.99

Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. J Clin Endocrinol Metab (2011) 0.94

Relationship of endogenous sex steroid hormones to lipids and apoproteins in postmenopausal women. Arteriosclerosis (1990) 0.93

Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls. J Clin Endocrinol Metab (2011) 0.93

A 20-year follow-up of young women with polycystic ovary syndrome. Obstet Gynecol (2012) 0.93

Clinical review: Lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause. J Clin Endocrinol Metab (2013) 0.90

Premenopausal antimüllerian hormone concentration is associated with subsequent atherosclerosis. Menopause (2012) 0.89

The phenotype of polycystic ovary syndrome ameliorates with aging. Fertil Steril (2011) 0.89

Does accelerated reproductive aging underlie premenopausal risk for cardiovascular disease? Menopause (2013) 0.87

Relative contributions of oligomenorrhea and hyperandrogenemia to the risk of metabolic syndrome in midlife women. J Clin Endocrinol Metab (2012) 0.86

Risk of cardiovascular events in patients with polycystic ovary syndrome. Neth J Med (2012) 0.82

Serum anti-Mullerian hormone (AMH) levels correlate with infrarenal aortic diameter in healthy older men: is AMH a cardiovascular hormone? J Endocrinol (2013) 0.81

Articles by these authors

The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril (2008) 5.31

Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab (2006) 4.56

Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol (2009) 3.63

Polycystic ovary syndrome. Lancet (2007) 3.62

Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med (2014) 3.57

Histological dating of timed endometrial biopsy tissue is not related to fertility status. Fertil Steril (2004) 3.03

Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril (2011) 2.80

HIV infection and bone mineral density in middle-aged women. Clin Infect Dis (2006) 2.67

Absence of secretory endometrium after false-positive home urine luteinizing hormone testing. Fertil Steril (2004) 2.59

Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis (2005) 2.55

Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab (2005) 2.50

Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med (2014) 2.48

Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab (2003) 2.47

Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2005) 2.28

Genomic profiling of microRNAs and messenger RNAs reveals hormonal regulation in microRNA expression in human endometrium. Biol Reprod (2009) 2.26

Duration of lactation is associated with lower prevalence of the metabolic syndrome in midlife--SWAN, the study of women's health across the nation. Am J Obstet Gynecol (2008) 2.15

B-type natriuretic peptide predicts left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. Echocardiography (2013) 2.06

Predictors of pregnancy in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2009) 1.90

Diminished paternity and gonadal function with increasing obesity in men. Fertil Steril (2008) 1.90

Family-based analysis of candidate genes for polycystic ovary syndrome. J Clin Endocrinol Metab (2010) 1.84

Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol (2003) 1.83

Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN). Am Heart J (2005) 1.67

Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility. N Engl J Med (2015) 1.65

Are vasomotor symptoms associated with sleep characteristics among symptomatic midlife women? Comparisons of self-report and objective measures. Menopause (2012) 1.65

Hyperandrogenism and hyperinsulinism in children of women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab (2008) 1.65

Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: study of Women's Health Across the Nation. Menopause (2009) 1.64

Less is more: increased gonadotropin use for ovarian stimulation adversely influences clinical pregnancy and live birth after in vitro fertilization. Fertil Steril (2008) 1.64

The effects of a whole grain-enriched hypocaloric diet on cardiovascular disease risk factors in men and women with metabolic syndrome. Am J Clin Nutr (2008) 1.63

Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab (2002) 1.63

Endometrial shedding effect on conception and live birth in women with polycystic ovary syndrome. Obstet Gynecol (2012) 1.62

Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women. Menopause (2015) 1.61

Women, hormones, and clinical trials: a beginning, not an end. J Appl Physiol (1985) (2005) 1.60

Circulating dehydroepiandrosterone sulfate levels in women who underwent bilateral salpingo-oophorectomy during the menopausal transition. Menopause (2011) 1.56

Urogenital symptoms and pain history as precursors of vulvodynia: a longitudinal study. J Womens Health (Larchmt) (2012) 1.54

Adverse effects of induced hot flashes on objectively recorded and subjectively reported sleep: results of a gonadotropin-releasing hormone agonist experimental protocol. Menopause (2013) 1.54

Implications of diminished ovarian reserve (DOR) extend well beyond reproductive concerns. Menopause (2008) 1.54

Ethnic differences in past hysterectomy for benign conditions. Womens Health Issues (2005) 1.52

Factors associated with vulvodynia incidence. Obstet Gynecol (2014) 1.52

Body image satisfaction and depression in midlife women: the Study of Women's Health Across the Nation (SWAN). Arch Womens Ment Health (2014) 1.51

Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J Med Genet (2011) 1.51

Pulsatile luteinizing hormone amplitude and progesterone metabolite excretion are reduced in obese women. J Clin Endocrinol Metab (2007) 1.50

Testosterone and visceral fat in midlife women: the Study of Women's Health Across the Nation (SWAN) fat patterning study. Obesity (Silver Spring) (2009) 1.49

Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis (2013) 1.49

Mood symptoms after natural menopause and hysterectomy with and without bilateral oophorectomy among women in midlife. Obstet Gynecol (2012) 1.47

Body shape and size and insulin resistance as early clinical predictors of hyperandrogenic anovulation in ethnic minority adolescent girls. J Adolesc Health (2008) 1.47

The relationship of circulating dehydroepiandrosterone, testosterone, and estradiol to stages of the menopausal transition and ethnicity. J Clin Endocrinol Metab (2002) 1.47

Ethnic differences in insulin sensitivity and beta-cell function in premenopausal or early perimenopausal women without diabetes: the Study of Women's Health Across the Nation (SWAN). Diabetes Care (2004) 1.45

Assessing comprehension of clinical research. Contemp Clin Trials (2011) 1.44

High serum levels of free cortisol indicate severity of cirrhosis in hemodynamically stable patients. J Gastroenterol Hepatol (2012) 1.43

Continuous glucose monitoring during pregnancy in women with polycystic ovary syndrome. Obstet Gynecol (2011) 1.42

Consistent ovulation may not be enough to make women healthy when approaching menopause: an update from the Study of Women's Health Across the Nation. Menopause (2015) 1.39

Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci U S A (2006) 1.38

Catechol-O-methyltransferase (COMT) single nucleotide polymorphisms and haplotypes are not major risk factors for polycystic ovary syndrome. Mol Cell Endocrinol (2011) 1.38

Identification of a polycystic ovary syndrome susceptibility variant in fibrillin-3 and association with a metabolic phenotype. J Clin Endocrinol Metab (2007) 1.37

Cardiovascular risk-factor knowledge and risk perception among HIV-infected adults. J Assoc Nurses AIDS Care (2013) 1.34

Factors related to age at natural menopause: longitudinal analyses from SWAN. Am J Epidemiol (2013) 1.34

Helping midlife women predict the onset of the final menses: SWAN, the Study of Women's Health Across the Nation. Menopause (2007) 1.34

Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab (2006) 1.30

Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. J Clin Endocrinol Metab (2010) 1.29

Gain in patients' knowledge of diabetes management targets is associated with better glycemic control. Diabetes Care (2007) 1.29

Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation. Am J Epidemiol (2009) 1.29

Femoral bone structural geometry adapts to mechanical loading and is influenced by sex steroids: the Penn State Young Women's Health Study. Bone (2004) 1.29

Overexpression of a DENND1A isoform produces a polycystic ovary syndrome theca phenotype. Proc Natl Acad Sci U S A (2014) 1.28

Menopause symptoms in HIV-infected and drug-using women. Menopause (2005) 1.27

Vasomotor symptom prevalence is associated with polymorphisms in sex steroid-metabolizing enzymes and receptors. Am J Med (2006) 1.25

HIV infection, drug use, and onset of natural menopause. Clin Infect Dis (2005) 1.24

Do changes in sex steroid hormones precede or follow increases in body weight during the menopause transition? Results from the Study of Women's Health Across the Nation. J Clin Endocrinol Metab (2012) 1.24

Quo vadis randomized controlled trials in infertility? Fertil Steril (2012) 1.23

Circulating dehydroepiandrosterone sulfate concentrations during the menopausal transition. J Clin Endocrinol Metab (2009) 1.22

Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis (2005) 1.22

Risk factors for falls in HIV-infected persons. J Acquir Immune Defic Syndr (2012) 1.20

Evidence for pancreatic beta-cell dysfunction in brothers of women with polycystic ovary syndrome. Metabolism (2008) 1.20

Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol (2007) 1.20

Evidence for chromosome 2p16.3 polycystic ovary syndrome susceptibility locus in affected women of European ancestry. J Clin Endocrinol Metab (2012) 1.19

Comparison of functional status instruments in HIV-infected adults on effective antiretroviral therapy. HIV Clin Trials (2012) 1.19

Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause (2006) 1.18

Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome. Mol Endocrinol (2004) 1.18

Evidence for association between polycystic ovary syndrome (PCOS) and TCF7L2 and glucose intolerance in women with PCOS and TCF7L2. J Clin Endocrinol Metab (2009) 1.17

Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab (2005) 1.17

Cardiovascular risk factor variation within a Hispanic cohort: SWAN, the Study of Women's Health Across the Nation. Ethn Dis (2010) 1.16

FTO and MC4R gene variants are associated with obesity in polycystic ovary syndrome. PLoS One (2011) 1.16

Diet drink consumption and the risk of cardiovascular events: a report from the Women's Health Initiative. J Gen Intern Med (2014) 1.15

Trajectory clustering of estradiol and follicle-stimulating hormone during the menopausal transition among women in the Study of Women's Health across the Nation (SWAN). J Clin Endocrinol Metab (2012) 1.15

The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome. Contemp Clin Trials (2012) 1.15

Menopausal symptoms and ethnicity: the Study of Women's Health Across the Nation. Womens Health (Lond Engl) (2009) 1.14

Relation of cardiovascular risk factors in women approaching menopause to menstrual cycle characteristics and reproductive hormones in the follicular and luteal phases. J Clin Endocrinol Metab (2006) 1.14

Risk factors for low bone mineral density and the 6-year rate of bone loss among premenopausal and perimenopausal women. Osteoporos Int (2004) 1.13

Decision trees for identifying predictors of treatment effectiveness in clinical trials and its application to ovulation in a study of women with polycystic ovary syndrome. Hum Reprod (2010) 1.13

Overweight men: clinical pregnancy after ART is decreased in IVF but not in ICSI cycles. J Assist Reprod Genet (2010) 1.12

The value of diastolic function parameters in the prediction of left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. Cardiovasc Ultrasound (2014) 1.11

Classifying menopause stage by menstrual calendars and annual interviews: need for improved questionnaires. Menopause (2013) 1.10

The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. Fertil Steril (2010) 1.09

Relationship of day-to-day reproductive hormone levels to sleep in midlife women. Arch Intern Med (2005) 1.08

Reproductive hormones and obesity: 9 years of observation from the Study of Women's Health Across the Nation. Am J Epidemiol (2010) 1.08

Age-related decline in fertility. Endocrinol Metab Clin North Am (2003) 1.08

Risk factors for stress fracture among young female cross-country runners. Med Sci Sports Exerc (2007) 1.07